Also known as Ozempic · Wegovy · Rybelsus
The once-weekly GLP-1 receptor agonist behind Ozempic, Wegovy, and Rybelsus — FDA-approved for type 2 diabetes, chronic weight management, cardiovascular risk reduction, and MASH.
Research refreshed
Semaglutide is a 31-amino-acid GLP-1 receptor agonist engineered for once-weekly dosing via fatty-acid acylation and amino-acid substitutions that resist DPP-4 degradation. It is FDA-approved for type 2 diabetes (Ozempic, 2017; oral Rybelsus, 2019), chronic weight management (Wegovy, 2021), cardiovascular risk reduction in adults with obesity and established heart disease (2024), and — as of August 2025 — metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis. The STEP-1 obesity trial reported ~14.9% mean weight reduction at 68 weeks.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist built on the backbone of human GLP-1. Two engineering changes define it: a C18 fatty-diacid chain attached through a linker that promotes reversible binding to albumin, and amino-acid substitutions that resist degradation by the enzyme DPP-4. Together these extend its half-life to roughly a week, enabling once-weekly administration. An oral formulation (Rybelsus) co-formulates the peptide with the absorption enhancer SNAC to protect it through the stomach.
Its pivotal data anchor the modern incretin era. The STEP-1 trial (Wilding et al., NEJM 2021, PMID 33567185) reported −14.9% mean body-weight change at 68 weeks on the 2.4 mg dose versus −2.4% on placebo — roughly 70% of participants lost at least 10% of body weight. The SELECT cardiovascular-outcomes trial reported a 20% reduction in major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease but without diabetes, leading to a dedicated CV indication in 2024; the SOUL trial (McGuire et al., NEJM 2025, PMID 40162642) then showed the oral formulation cuts MACE by 14% in high-risk type 2 diabetes.
The liver program is the most recent expansion. The ESSENCE Phase 3 trial (Sanyal et al., NEJM 2025, PMID 40305708) reported resolution of steatohepatitis without worsening of fibrosis in 62.9% of participants on semaglutide 2.4 mg versus 34.3% on placebo at 72 weeks, and in August 2025 the FDA granted accelerated approval of Wegovy for noncirrhotic MASH with moderate-to-advanced fibrosis. Semaglutide’s acylation-plus-DPP-4-resistance template now informs the entire incretin class — dual agonists like tirzepatide and triple agonists like retatrutide are its molecular descendants.
GLP-1 receptor agonism → glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and central appetite suppression.
Behind every vial of Semaglutide is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Semaglutide, specifically, is brought into being.
On paper, Semaglutide is C187H291N45O59 — about 4,113.6 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Semaglutide is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later. It also carries fatty-acid acylation, an extra step beyond a plain chain that adds both capability and cost.
The crude mixture — Semaglutide plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Semaglutide proves itself: identity confirmed by mass spectrometry against its ~4,113.6 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Semaglutide — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Beyond its 31-residue chain, semaglutide carries a fatty-diacid side chain on a linker — extra synthetic steps that each add cost and another opportunity for impurities to form. Genuine material is purified to a defined spec and documented on a certificate of analysis, never judged by appearance.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Semaglutide, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
Semaglutide is a long-acting GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy), cardiovascular risk reduction in obesity with established heart disease, and — since August 2025 — MASH with moderate-to-advanced fibrosis.
In the pivotal STEP-1 trial (NEJM 2021), adults on semaglutide 2.4 mg lost a mean of 14.9% of body weight at 68 weeks versus 2.4% on placebo; about 70% lost at least 10%, and about half lost at least 15%. These are trial population means, not individual predictions.
All three are semaglutide. Ozempic (weekly injection) and Rybelsus (daily oral tablet) are approved for type 2 diabetes; Wegovy (weekly injection, higher 2.4 mg dose) is approved for chronic weight management, cardiovascular risk reduction, and MASH. This page is a research reference, not medical advice.
Yes — in August 2025 the FDA granted accelerated approval of Wegovy for adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis, based on the ESSENCE Phase 3 trial (62.9% steatohepatitis resolution versus 34.3% placebo at 72 weeks).
The most common adverse events in trials are gastrointestinal — nausea, vomiting, diarrhea, and constipation — usually during dose escalation. The label carries a boxed warning about thyroid C-cell tumors seen in rodent studies. This page is a research reference, not medical advice.
A fatty-diacid side chain lets it bind reversibly to albumin, and amino-acid substitutions resist breakdown by the enzyme DPP-4 — together stretching GLP-1’s natural minutes-long half-life to about one week.
Semaglutide activates GLP-1 alone; tirzepatide adds GIP (dual agonist, ~22.5% mean weight loss in SURMOUNT-1) and retatrutide adds both GIP and glucagon (triple agonist, ~28.7% in the first Phase 3 readout). Cross-trial comparisons are not head-to-head; semaglutide remains the most extensively studied and broadly approved of the three.
Yes — a 31-residue analog of human GLP-1 (~4,113.6 Da) built by solid-phase synthesis, with a C18 fatty-diacid chain on a linker attached to a lysine. The oral Rybelsus form co-formulates the same peptide with the SNAC absorption enhancer.
The once-daily GLP-1 agonist that preceded semaglutide — FDA-approved for diabetes (Victoza) and obesity (Saxenda).
ViewDual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.
ViewInvestigational once-weekly triple agonist (GIP / GLP-1 / glucagon) — the molecule some in the research community nickname "GLP-3" — with the largest weight reductions reported for any incretin-class agent.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.